Invesco
HRMY icon

Invesco’s Harmony Biosciences HRMY Stock Holding History

Invesco’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2M Sell
528,520
-99,727
-16% -$3.15M ﹤0.01% 1525
2026
Q1 		$17.6M Buy
628,247
+177,442
+39% +$5.82M ﹤0.01% 1518
2025
Q4 		$16.9M Buy
450,805
+47,517
+12% +$1.56M ﹤0.01% 1556
2025
Q3 		$11.1M Buy
403,288
+2,341
+0.6% +$80.6K ﹤0.01% 1764
2025
Q2 		$12.7M Sell
400,947
-42,740
-10% -$1.37M ﹤0.01% 1637
2025
Q1 		$14.7M Sell
443,687
-5,493
-1% -$197K ﹤0.01% 1579
2024
Q4 		$15.5M Buy
449,180
+285,156
+174% +$9.8M ﹤0.01% 1619
2024
Q3 		$6.56M Buy
164,024
+13,090
+9% +$460K ﹤0.01% 2064
2024
Q2 		$4.55M Buy
150,934
+17,026
+13% +$512K ﹤0.01% 2246
2024
Q1 		$4.5M Buy
133,908
+19,732
+17% +$633K ﹤0.01% 2302
2023
Q4 		$3.69M Sell
114,176
-12,267
-10% -$342K ﹤0.01% 2388
2023
Q3 		$4.14M Sell
126,443
-20,986
-14% -$729K ﹤0.01% 2305
2023
Q2 		$5.19M Sell
147,429
-806,902
-85% -$27.9M ﹤0.01% 2220
2023
Q1 		$31.2M Sell
954,331
-721,445
-43% -$32.9M 0.01% 1152
2022
Q4 		$92.3M Buy
1,675,776
+506,041
+43% +$27.8M 0.03% 737
2022
Q3 		$51.8M Buy
1,169,735
+909,677
+350% +$44.4M 0.02% 898
2022
Q2 		$12.7M Buy
260,058
+57,750
+29% +$2.6M ﹤0.01% 1676
2022
Q1 		$9.84M Buy
202,308
+91,947
+83% +$3.75M ﹤0.01% 1973
2021
Q4 		$4.71M Buy
110,361
+100,902
+1,067% +$4.02M ﹤0.01% 2432
2021
Q3 		$362K Buy
9,459
+1,911
+25% +$61.5K ﹤0.01% 3571
2021
Q2 		$213K Buy
+7,548
New +$226K ﹤0.01% 3767

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's HRMY Position: Q2 2026 in Review

Invesco reduced its Harmony Biosciences (HRMY) stake by 16% in Q2 2026, selling an estimated $3.15M and leaving 528,520 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Invesco first reported a position in HRMY in Q2 2021 and has held it in 21 quarters since. The position peaked at $92.3M in Q4 2022. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Invesco held 528,520 shares of Harmony Biosciences worth $19.2M as of Q2 2026.
  • Invesco sold 99,727 Harmony Biosciences shares in Q2 2026, an estimated $3.15M.
  • Harmony Biosciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1525 holding.
  • Invesco first reported a position in Harmony Biosciences in Q2 2021 and has held it in 21 quarters since.
  • Invesco's Harmony Biosciences position peaked at $92.3M in Q4 2022.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.